Added Value of Soluble Tumor Necrosis Factor-α Receptor 1 as a Biomarker of ESRD Risk in Patients With Type 1 Diabetes
Carol Forsblom(University of Helsinki), Merlin C. Thomas(Monash University), Per‐Henrik Groop(University of Helsinki), Markku Saraheimo(Helsinki University Hospital), Tony Loughman(EKF Diagnostics (United States)), Daniel Gordin(Helsinki University Hospital), Valma Harjutsalo(Research Council of Finland), Lena M. Thorn(University of Helsinki), Nina Tolonen(University of Helsinki), John L. Moran(Queen Victoria Hospital), Johan Wadén(Helsinki University Hospital)
Cited by 49
Related Papers
Diabetic kidney disease
|Nature Reviews Disease Primers|2015|1.2k
Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study
|The Lancet|2008|665
The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes
|Diabetes|2009|641
Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
|Journal of the American Society of Nephrology|2013|578